ATE113839T1 - Arzneimittel gegen impotenz. - Google Patents

Arzneimittel gegen impotenz.

Info

Publication number
ATE113839T1
ATE113839T1 AT91304430T AT91304430T ATE113839T1 AT E113839 T1 ATE113839 T1 AT E113839T1 AT 91304430 T AT91304430 T AT 91304430T AT 91304430 T AT91304430 T AT 91304430T AT E113839 T1 ATE113839 T1 AT E113839T1
Authority
AT
Austria
Prior art keywords
impotence
medications against
relieving
male
erectile impotence
Prior art date
Application number
AT91304430T
Other languages
English (en)
Inventor
George Mclean Milne
Michael Grant Wyllie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE113839T1 publication Critical patent/ATE113839T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Harvester Elements (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Tone Control, Compression And Expansion, Limiting Amplitude (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Saccharide Compounds (AREA)
AT91304430T 1990-05-31 1991-05-17 Arzneimittel gegen impotenz. ATE113839T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53149490A 1990-05-31 1990-05-31

Publications (1)

Publication Number Publication Date
ATE113839T1 true ATE113839T1 (de) 1994-11-15

Family

ID=24117862

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91304430T ATE113839T1 (de) 1990-05-31 1991-05-17 Arzneimittel gegen impotenz.

Country Status (15)

Country Link
EP (1) EP0459666B1 (de)
JP (1) JP2522609B2 (de)
KR (1) KR930010582B1 (de)
AT (1) ATE113839T1 (de)
AU (1) AU620282B2 (de)
CA (1) CA2043440C (de)
DE (1) DE69105040T2 (de)
DK (1) DK0459666T3 (de)
HU (1) HU208076B (de)
IE (1) IE63837B1 (de)
IL (1) IL98258A (de)
MY (1) MY106528A (de)
NZ (1) NZ238339A (de)
PT (1) PT97785B (de)
ZA (1) ZA914135B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
ES2146249T3 (es) * 1993-02-10 2000-08-01 Bmra Corp Bv Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
MX9703518A (es) 1994-11-16 1997-08-30 Synaptic Pharma Corp Dihidropirimidinas y usos de las mismas.
CA2215307A1 (en) * 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
BR9709230A (pt) * 1996-05-10 1999-08-10 Icos Corp Composto
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
DE59611417D1 (de) * 1996-12-20 2007-03-29 Heumann Pharma Gmbh & Co Neue polymorphe Form von Doxazosinmesylat (Form III)
CA2314993A1 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
DE19800214A1 (de) 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
EP1280531B1 (de) * 2000-05-12 2007-01-24 Novalar Pharmaceuticals, Inc. Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions

Also Published As

Publication number Publication date
KR910019618A (ko) 1991-12-19
JPH04235917A (ja) 1992-08-25
CA2043440C (en) 1996-07-30
HU208076B (en) 1993-08-30
KR930010582B1 (ko) 1993-10-30
DE69105040D1 (de) 1994-12-15
IL98258A0 (en) 1992-06-21
PT97785A (pt) 1992-02-28
MY106528A (en) 1995-06-30
NZ238339A (en) 1997-07-27
ZA914135B (en) 1993-01-27
IE911842A1 (en) 1991-12-04
CA2043440A1 (en) 1991-12-01
PT97785B (pt) 1999-01-29
HUT58520A (en) 1992-03-30
IE63837B1 (en) 1995-06-14
DE69105040T2 (de) 1995-03-23
AU7807791A (en) 1991-12-05
EP0459666B1 (de) 1994-11-09
IL98258A (en) 1996-01-31
EP0459666A3 (en) 1992-06-03
DK0459666T3 (da) 1994-12-05
AU620282B2 (en) 1992-02-13
JP2522609B2 (ja) 1996-08-07
EP0459666A2 (de) 1991-12-04
HU911810D0 (en) 1991-12-30

Similar Documents

Publication Publication Date Title
ATE113839T1 (de) Arzneimittel gegen impotenz.
ATE145551T1 (de) Brausedosisform sowie verfahren zu deren verabreichung
TW273550B (de)
ATE168268T1 (de) Behandlung von menschlichen retrovirus- infektionen mit 2',3'-dideoxyinosin
DE69507493D1 (de) Tirilazad parentale formulierung mit einem co-lösungsmittel
ATA195588A (de) Epipodophyllotoxinglucosid-4'-phosphat-derivate deren herstellung, sowie pharmazeutische zusammensetzungen hierzu
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
ATE198835T1 (de) Knochenwachstumsfördernde zusammensetzung
NO922936D0 (no) Fremstilling av fettsyremedikamenter
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
FI945510A0 (fi) Klavulaanihapon diamiinisuolat
EP0362847A3 (de) Verwendung von Etoperidon zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von männlicher Impotenz
BG101884A (en) Salts of the clavulanic acid
TW366284B (en) Pharmaceutical antitussive composition of delta-receptor antagonist
IT9086204A0 (it) Metodo per la cura dell'impotenza erettiva maschile
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
DK0458587T3 (da) Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
FI943875L (fi) 2,3,4,5-Tetrahydro-1H-3-bentsatsepiinejä ja niiden farmaseuttisesti hyväksyttäviä happoadditiosuoloja
ITRM910550A0 (it) Preparazioni farmaceutiche orali, a base di acidi biliari, a cessione protratta e controllata con le quali e' possibile adottare una sola somministrazione giornaliera
RU93044256A (ru) Способ лечения саркоидоза
EP0482919A3 (en) Method and composition for treating leg weakness in fowl by the administration of a non-steroidal anti-inflammatory drug
LES DEUX THE FREE RADICAL CLUB CERLIB

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee